Research Topics
| Benedetto VitielloSummaryAffiliation: National Institutes of Health Country: USA Publications
| Collaborators
|
Detail Information
Publications
Improving decision making in the treatment of ADHDBenedetto Vitiello
Am J Psychiatry 165:666-7. 2008
Treatment moderators and predictors of outcome in the Treatment of Early Age Mania (TEAM) studyBenedetto Vitiello
National Institute of Mental Health, Bethesda, MD 20892 9633, USA
J Am Acad Child Adolesc Psychiatry 51:867-78. 2012..We searched for treatment moderators and predictors of outcome...
Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHDBenedetto Vitiello
NIMH, Bethesda, MD, USA
Am J Psychiatry 169:167-77. 2012..The authors examined the association between stimulant medication and blood pressure and heart rate over 10 years...- Children's hospitalizations with a mood disorder diagnosis in general hospitals in the united states 2000-2006Tamar Lasky
MIE Resources, Kingston, Rhode Island, USA
Child Adolesc Psychiatry Ment Health 5:27. 2011..abstract:.. - The role of anxiety symptoms in school performance in a community sample of children and adolescentsLuigi Mazzone
Division of Child Neurology and Psychiatry Department of Paediatrics, University of Catania, Catania, Italy
BMC Public Health 7:347. 2007..The prevalence of anxiety and the relationship between anxiety and school performance were examined among elementary, middle, and high school students... - A depressed adolescent at high risk of suicidal behaviorBenedetto Vitiello
Division of Services and Intervention Research, NIMH, NIH, Bethesda, MD 20892-9633, USA
Am J Psychiatry 165:323-8; quiz 408. 2008 - An update on publicly funded multisite trials in pediatric psychopharmacologyBenedetto Vitiello
National Institute of Mental Health, Room 7147, 6001 Executive Boulevard, MSC 9633, Bethesda, MD 20892 9633, USA
Child Adolesc Psychiatr Clin N Am 15:1-12. 2006..This article presents a brief overview of these studies... - Assessment of the integrity of study blindness in a pediatric clinical trial of risperidoneBenedetto Vitiello
Division of Services and Intervention Research, National Institute of Mental Health, Bethesda, MD 20892 9633, USA
J Clin Psychopharmacol 25:565-9. 2005..The blindness of clinical evaluators and parents was examined in a clinical trial of risperidone in autism... - An international perspective on pediatric psychopharmacologyBenedetto Vitiello
National Institute of Mental Health, Bethesda, MD 20892 9633, USA
Int Rev Psychiatry 20:121-6. 2008..A better understanding of the factors underlying international variability may help clarify the process of diagnosis and treatment selection in child and adolescent psychiatry... - Combined cognitive-behavioural therapy and pharmacotherapy for adolescent depression: Does it improve outcomes compared with monotherapy?Benedetto Vitiello
National Institute of Mental Health, Bethesda, Maryland 20892 9633, USA
CNS Drugs 23:271-80. 2009..It remains to be determined for which patient subgroups and in which clinical settings COMB may be most advantageous... - National estimates of antidepressant medication use among U.S. children, 1997-2002Benedetto Vitiello
Child and Adolescent Treatment and Preventive Intervention Research Branch, National Institute of Mental Health, Bethesda, MD, USA
J Am Acad Child Adolesc Psychiatry 45:271-9. 2006..3%) and 1996 (1.0%). The aim of this study was to determine whether pediatric use of antidepressants continued to rise at a national level during the period 1997-2002... - Blindness of clinical evaluators, parents, and children in a placebo-controlled trial of fluvoxamineBenedetto Vitiello
National Institute of Mental Health, Bethesda, Maryland 20892, USA
J Child Adolesc Psychopharmacol 16:219-25. 2006..The success of the masking procedures used in a double-blind, pediatric trial of fluvoxamine in children was examined... - Hyperforin plasma level as a marker of treatment adherence in the National Institutes of Health Hypericum Depression TrialBenedetto Vitiello
National Institute of Mental Health, Bethesda, MD 20892 9633, USA
J Clin Psychopharmacol 25:243-9. 2005..We assessed treatment adherence by measuring plasma hyperforin and evaluated the possible impact of adherence on study results... - Research in child and adolescent psychopharmacology: recent accomplishments and new challengesBenedetto Vitiello
Child and Adolescent Treatment and Preventive Intervention Research Branch, National Institute of Mental Health, Room 7147, 6001 Executive Blvd, MSC 9633, Bethesda, MD 20892 9633, USA
Psychopharmacology (Berl) 191:5-13. 2007..Still, controversy remains about the effectiveness and safety of commonly used psychotropics and their role in child treatment, thus pointing to the need for more in-depth and targeted investigations... - Functioning and quality of life in the Treatment for Adolescents with Depression Study (TADS)Benedetto Vitiello
J Am Acad Child Adolesc Psychiatry 45:1419-26. 2006..To test whether 12-week treatment of major depression improved the level of functioning, global health, and quality of life of adolescents... - Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular functionBenedetto Vitiello
Child and Adolescent Treatment and Preventive Intervention Research Branch, Division of Services and Intervention Research, National Institute of Mental Health, Room 7147, 6001 Executive Boulevard, Bethesda, MD 20892 9633, USA
Child Adolesc Psychiatr Clin N Am 17:459-74, xi. 2008..More research is needed to elucidate the mechanism of growth suppression to estimate better the risk for rare but life-threatening events and test the effectiveness of monitoring procedures... - Research knowledge among the participants in the Treatment for Adolescents With Depression Study (TADS)Benedetto Vitiello
Division of Services and Intervention Research, National Institute of Mental Health, Bethesda, MD 20892 9633, USA
J Am Acad Child Adolesc Psychiatry 46:1642-50. 2007..We examined the extent to which parents and adolescents participating in the Treatment for Adolescents With Depression Study (TADS) understood key aspects of the study... - HIV-1 RNA concentration and cognitive performance in a cohort of HIV-positive peopleBenedetto Vitiello
Institute of Mental Health, Bethesda, Maryland 20892, USA
AIDS 21:1415-22. 2007..To determine whether higher viral concentrations in the cerebrospinal fluid (CSF) and/or peripheral blood were associated with greater severity of cognitive impairment in HIV-1-seropositive subjects with cognitive-motor impairment... - Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concernsBenedetto Vitiello
National Institute of Mental Health, Room 7147, 6001 Executive Blvd, Bethesda, MD 20892 9633, USA
Eur Neuropsychopharmacol 19:629-35. 2009..Research is also needed to understand the mechanisms underlying antipsychotic-induced toxicities in order to develop effective preventive and treatment strategies... - Suicidal events in the Treatment for Adolescents With Depression Study (TADS)Benedetto Vitiello
NIMH, NIH, Bethesda, MD 20892 9633, USA
J Clin Psychiatry 70:741-7. 2009.... - Ethical considerations in psychopharmacological research involving children and adolescentsBenedetto Vitiello
Child and Adolescent Treatment and Preventive Intervention Research Branch, NIMH, MSC 9633, Bethesda, MD 20892 9633, USA
Psychopharmacology (Berl) 171:86-91. 2003..Increased community utilization of psychotropic medications among children has brought attention to pediatric psychopharmacology research and associated ethical issues... - Government initiatives in autism clinical trialsBenedetto Vitiello
Division of Services and Intervention Research, National Institute of Mental Health, Bethesda, Maryland 20892 9633, USA
CNS Spectr 9:66-70. 2004..These and other government activities in the area of autism clinical trials are here briefly reviewed... - Prevention and treatment of child and adolescent depression: challenges and opportunitiesB Vitiello
National Institute of Mental Health, Bethesda, MD, USA
Epidemiol Psychiatr Sci 20:37-43. 2011..To examine the current theoretical rationale and empirical evidence for preventing and treating major depressive disorder in childhood and adolescence... - Long-term outcome of adolescent depression initially resistant to selective serotonin reuptake inhibitor treatment: a follow-up study of the TORDIA sampleBenedetto Vitiello
Division of Services and Intervention Research, National Institute of Mental Health, Room 7147, 6001 Executive Blvd, Bethesda, MD 20892 9633, USA
J Clin Psychiatry 72:388-96. 2011..Responders then continued with the same treatment through week 24, while nonresponders were given open treatment... - Depressive symptoms and clinical status during the Treatment of Adolescent Suicide Attempters (TASA) StudyBenedetto Vitiello
National Institute of Mental Health, Bethesda, MD 20892 9633, USA
J Am Acad Child Adolesc Psychiatry 48:997-1004. 2009..To examine the course of depression during the treatment of adolescents with depression who had recently attempted suicide... - Pharmacoepidemiology and pediatric psychopharmacology researchBenedetto Vitiello
National Institute of Mental Health, Room 7147, 6001 Executive Boulevard, MSC 9633, Bethesda, MD 20892-9633, USA
J Child Adolesc Psychopharmacol 15:10-1. 2005 - Research knowledge among parents of children participating in a randomized clinical trialBenedetto Vitiello
Child and Adolescent Treatment and Preventive Intervention Research Branch, National Institute of Mental Health, Bethesda, MD 20892 9633, USA
J Am Acad Child Adolesc Psychiatry 44:145-9. 2005..Parental permission is required for child research, but parents' understanding of research aims and procedures has not been well documented. Parental research knowledge was assessed during a clinical trial in autism... - Parent satisfaction in a multi-site acute trial of risperidone in children with autism: a social validity studyElaine Tierney
Department of Psychiatry, Kennedy Krieger Institute, Baltimore, MD, USA
Psychopharmacology (Berl) 191:149-57. 2007..Designing studies that consider the consumer's perspective will help to forge a better alliance between participants and researchers... - How can we improve the assessment of safety in child and adolescent psychopharmacology?Benedetto Vitiello
Division of Services and Intervention Research, NIMH, Bethesda, MD 20982 9633, USA
J Am Acad Child Adolesc Psychiatry 42:634-41. 2003..To identify approaches to improving methods for assessing tolerability and safety of psychotropic medications in children and adolescents... - Effectiveness of methylphenidate in the 10-month continuation phase of the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS)Benedetto Vitiello
Child and Adolescent Treatment and Preventive Intervention Research Branch, National Institute of Mental Health, 6001 Executive Boulevard, Bethesda, MD 20892, USA
J Child Adolesc Psychopharmacol 17:593-604. 2007..The aim of this study was to examine immediate-release methylphenidate effectiveness during the 10-month open-label continuation phase of the Preschoolers with Attention-Deficit/Hyperactivity Disorder (ADHD) Treatment Study (PATS)... - Recent trends in stimulant medication use among U.S. childrenSamuel H Zuvekas
Division of Services and Intervention Research, NIMH, 6001 Executive Blvd, Bethesda, MD 20892-9633, USA
Am J Psychiatry 163:579-85. 2006.... - Economic evaluation of strategies to reduce sudden cardiac death in young athletesMichael Schoenbaum
National Institute of Mental Health, 6001 Executive Blvd, Room 8225 MSC 9669, Bethesda, MD 20892, USA
Pediatrics 130:e380-9. 2012..The objective of this study was to evaluate the cost-effectiveness of adding electrocardiogram (ECG) screening to the currently standard practice of preparticipation history and physical examination (H&P) to reduce SCD... - Stimulant medication use in children: a 12-year perspectiveSamuel H Zuvekas
Center for Financing, Access, and Cost Trends, Agency for Healthcare Research and Quality, Rockville, MD, USA
Am J Psychiatry 169:160-6. 2012..The authors examined the utilization of stimulant medications for the treatment of ADHD in U.S. children during the period 1996–2008 to determine trends by age, sex, race/ethnicity, family income, and geographic region... - Use of psychotropic medications among HIV-infected patients in the United StatesBenedetto Vitiello
Division of Services and Intervention Research, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892 9633, USA
Am J Psychiatry 160:547-54. 2003..This study describes the prevalence and pattern of use of psychotropic medications by HIV-positive patients receiving medical care in the United States and the search for possible predictors of use... - Developmental disabilities modification of the Children's Global Assessment ScaleAnn Wagner
National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA
Biol Psychiatry 61:504-11. 2007..To measure global functioning in treatment studies, the Children's Global Assessment Scale was modified and psychometric properties of the revised version (DD-CGAS) were assessed in children with PDD... - The interface between publicly funded and industry-funded research in pediatric psychopharmacology: opportunities for integration and collaborationBenedetto Vitiello
Child and Adolescent Treatment and Preventive Intervention Research Branch, Division of Services and Intervention Research, National Institute of Mental Health, Bethesda, Maryland, USA
Biol Psychiatry 56:3-9. 2004.... - Introduction: issues and viewpoints in pediatric psychopharmacologyMark A Riddle
Division of Child and Adolescent Psychiatry, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Int Rev Psychiatry 20:119-20. 2008 - Approaches to multisite clinical trials: the National Institute of Mental Health perspectiveBarry D Lebowitz
Adult and Geriatric Treatment and Preventive Intervention Research Branch, Division of Services and Intervention Research, National Institute of Mental Health, Bethesda, MD 20892 9635, USA
Schizophr Bull 29:7-13. 2003..Finally, we enumerate some of the pitfalls of large clinical trials and discuss measures taken to anticipate and address them... - Antidepressant medications in childrenBenedetto Vitiello
National Institute of Mental Health, Bethesda, MD, USA
N Engl J Med 350:1489-91. 2004 - Modeled economic evaluation of alternative strategies to reduce sudden cardiac death among children treated for attention deficit/hyperactivity disorderPeter Denchev
Division of Services and Intervention Research, National Institute of Mental Health, 6001 Executive Blvd, Bethesda, MD 20892, USA
Circulation 121:1329-37. 2010..Relative cost-effectiveness may be improved by basing cardiology referral on ECG alone. Benefits of ECG screening arise primarily by restricting children identified with SCD risk from competitive sports... - Pubertal delay in male nonhuman primates (Macaca mulatta) treated with methylphenidateDonald R Mattison
Epidemiology Branch, Division of Epidemiology, Statistics, and Prevention Research, The Eunice Kennedy Shriver National Institute for Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA
Proc Natl Acad Sci U S A 108:16301-6. 2011..Regardless, deficits in testicular volume and hormone secretion disappeared over the 40-mo observation period, suggesting that the impact of MPH on puberty is not permanent... - Acute time to response in the Treatment for Adolescents with Depression Study (TADS)Christopher Kratochvil
University of Nebraska Medical Center NE 68198 5581, USA
J Am Acad Child Adolesc Psychiatry 45:1412-8. 2006..To examine the time to response for both pharmacotherapy and psychotherapy in the Treatment for Adolescents with Depression Study (TADS)... - Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacologyChristopher J McDougle
Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN 46202 4800, USA
Am J Psychiatry 162:1142-8. 2005..The authors report on whether risperidone improves the core symptoms of autism, social and communication impairment and repetitive and stereotyped behavior... - Achievement and maintenance of sustained response during the Treatment for Adolescents With Depression Study continuation and maintenance therapyPaul Rohde
Oregon Research Institute, 1715 Franklin Blvd, Eugene, OR 97403 1983, USA
Arch Gen Psychiatry 65:447-55. 2008..Treatment consisted of 3 stages: (1) acute (12 weeks), (2) continuation (6 weeks), and (3) maintenance (18 weeks)... - Cost-effectiveness of ADHD treatments: findings from the multimodal treatment study of children with ADHDPeter S Jensen
Center for the Advancement of Children s Mental Health, Department of Child Psychiatry, New York State Psychiatric Institute, Columbia University, 1051 Riverside Dr, Suite 78, New York, NY 10032, USA
Am J Psychiatry 162:1628-36. 2005..To the authors' knowledge, this is the first study on the cost-effectiveness of the major forms of ADHD treatments used in NIMH's Multimodal Treatment Study of Children With ADHD (MTA Study)... - Comparative efficacy of cognitive behavioral therapy, fluoxetine, and their combination in depressed adolescents: initial lessons from the treatment for adolescents with depression studySanjeev Pathak
University of Cincinnati College of Medicine, Children s Hospital Medical Center, MLC D 3014, 3333 Burnet Avenue, Cincinnati, OH 45229, USA
Curr Psychiatry Rep 7:429-34. 2005..Moreover, the study results confirm that fluoxetine alone is effective in the treatment of depressed adolescents... - Acute and long-term safety and tolerability of risperidone in children with autismMichael G Aman
The Nisonger Center, Ohio State University, Columbus, Ohio 43210 1296, USA
J Child Adolesc Psychopharmacol 15:869-84. 2005..Most AEs were mild to moderate and failed to interfere with therapeutic changes; there were no unanticipated AEs. The side effects of most concern were somnolence and weight gain... - Assessing medication effects in the MTA study using neuropsychological outcomesJeffery N Epstein
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA
J Child Psychol Psychiatry 47:446-56. 2006.... - Emergency/Adjunct services and attrition prevention for randomized clinical trials in children: the MTA manual-based solutionHoward Abikoff
Child and Adolescent Psychiatry, NYU Child Study Center, NYU School of Medicine, NY 10016, USA
J Am Acad Child Adolesc Psychiatry 41:498-504. 2002..Although the manual-based guidelines are especially applicable to multisite RCTs, many of the procedures in the ASAP Manual can apply to any treatment study in children... - Sequential pharmacotherapy for children with comorbid attention-deficit/hyperactivity and anxiety disordersHoward Abikoff
New York University Child Study Center, New York, NY 10016, USA
J Am Acad Child Adolesc Psychiatry 44:418-27. 2005..This study examined the efficacy of sequential pharmacotherapy for ADHD/ANX children... - Treatment-related changes in objectively measured parenting behaviors in the multimodal treatment study of children with attention-deficit/hyperactivity disorderKaren C Wells
Department of Psychiatry, Duke University Medical Center, Durham, NC, USA
J Consult Clin Psychol 74:649-57. 2006..The authors discuss the importance of changes in parenting behavior for families of children with ADHD and the need for reliable and objective measures in evaluating treatment outcome... - Assessing patient beliefs in a clinical trial of Hypericum perforatum in major depressionCarla M Bann
RTI International, Research Triangle Park, North Carolina 27709 2194, USA
Depress Anxiety 20:114-22. 2004..Future studies should explore whether patient beliefs have an even greater impact when patients are aware of the treatment they are receiving and can determine whether that treatment is consistent with their beliefs... - National trends in concomitant psychotropic medication with stimulants in pediatric visits: practice versus knowledgeVinod Bhatara
University of South Dakota, Psychiatry and Family Medicine, USA
J Atten Disord 7:217-26. 2004.... - Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trialJohn March
Duke Clinical Research Institute, Department of Psychiatry, Duke University Medical Center, Durham, NC 27710, USA
JAMA 292:807-20. 2004..Initial treatment of major depressive disorder in adolescents may include cognitive-behavioral therapy (CBT) or a selective serotonin reuptake inhibitor (SSRI). However, little is known about their relative or combined effectiveness... - Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trialsL Eugene Arnold
Ohio State University, 479 S Galena Road, Sunbury, OH 43074, USA
J Am Acad Child Adolesc Psychiatry 42:1443-50. 2003..A consumer-oriented efficacy assessment in clinical trials should measure changes in chief complaint and consumer request (symptoms of most concern to patient/caregiver), which may be diluted in change scores of multisymptom scales... - Effects of ethnicity on treatment attendance, stimulant response/dose, and 14-month outcome in ADHDL Eugene Arnold
Department of Psychiatry, Ohio State University, USA
J Consult Clin Psychol 71:713-27. 2003..Treatment for lower socioeconomic status minority children, especially if comorbid, should combine medication and behavioral treatment... - Review of safety assessment methods used in pediatric psychopharmacologyLaurence L Greenhill
New York State Psychiatric Institute Columbia University, New York 10032, USA
J Am Acad Child Adolesc Psychiatry 42:627-33. 2003..Elicitation is an essential and critical step in ascertaining adverse events (AEs). This report reviews elicitation methods used in published clinical trials of psychopharmacological agents in children... - Treatment of pediatric anxiety disorders: an open-label extension of the research units on pediatric psychopharmacology anxiety studyJohn Walkup
Johns Hopkins University, USA
J Child Adolesc Psychopharmacol 12:175-88. 2002..Results suggest that an initial fluvoxamine response is likely to be retained with continued treatment, that some fluvoxamine nonresponders may respond to fluoxetine, and that some placebo nonresponders may respond to fluvoxamine... - Children's Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disordersLawrence Scahill
Yale Child Study Center, Yale University, New Haven, CT 06520, USA
J Am Acad Child Adolesc Psychiatry 45:1114-23. 2006..To examine the psychometric properties of the Children's Yale-Brown Obsessive Compulsive Scales (CYBOCS) modified for pervasive developmental disorders (PDDs)... - Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHDLaurence Greenhill
Division of Child and Adolescent Psychiatry, New York State Psychiatric Institute Columbia University, New York, NY 10032, USA
J Am Acad Child Adolesc Psychiatry 45:1284-93. 2006..i.d. to children ages 3 to 5.5 years with attention-deficit/hyperactivity disorder (ADHD)... - Treatment of early-onset schizophrenia spectrum disorders (TEOSS): rationale, design, and methodsJon McClellan
University of Washington, Seattle, USA
J Am Acad Child Adolesc Psychiatry 46:969-78. 2007..The rationale, design, and methods of the Treatment of Early Onset Schizophrenia Spectrum Disorders Study are described... - The Treatment for Adolescents with Depression Study (TADS): methods and message at 12 weeksJohn March
Department of Psychiatry, Durham, NC 27710, USA
J Am Acad Child Adolesc Psychiatry 45:1393-403. 2006..Taking benefit and risk into account, we conclude that the combination of FLX and CBT appears superior to either monotherapy as a treatment for moderate to severe major depressive disorder in adolescents... - Texas Children's Medication Algorithm Project: update from Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive DisorderCarroll W Hughes
Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390 8589, USA
J Am Acad Child Adolesc Psychiatry 46:667-86. 2007..To revise and update consensus guidelines for medication treatment algorithms for childhood major depressive disorder based on new scientific evidence and expert clinical consensus when evidence is lacking... - Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measuresDavid J Posey
Department of Psychiatry, Indiana University School of Medicine, Indianapolis, Indiana, USA
Biol Psychiatry 61:538-44. 2007.... - Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS)Betsy Kennard
UT Southwestern Medical Center, Dallas, TX 75390 8589, USA
J Am Acad Child Adolesc Psychiatry 45:1404-11. 2006.... - Dietary status and impact of risperidone on nutritional balance in children with autism: a pilot studyRonald L Lindsay
Children s Health Center of St Joseph s Hospital and Medical Center, Arizona 85013, USA
J Intellect Dev Disabil 31:204-9. 2006..Risperidone may be effective in improving tantrums, aggression, or self-injurious behaviour in children with autism, but often leads to weight gain... - Treatment for Adolescents with Depression Study (TADS): safety resultsGraham Emslie
UT Southwestern Medical Centre at Dallas, TX 75390 8589, USA
J Am Acad Child Adolesc Psychiatry 45:1440-55. 2006..To compare the rates of physical, psychiatric, and suicide-related events in adolescents with MDD treated with fluoxetine alone (FLX), cognitive-behavioral therapy (CBT), combination treatment (COMB), or placebo (PBO)... - Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS)John Curry
Duke Child and Family Study Center, NC 27705, USA
J Am Acad Child Adolesc Psychiatry 45:1427-39. 2006.... - Treatment of early-onset schizophrenia spectrum disorders (TEOSS): demographic and clinical characteristicsJean A Frazier
Cambridge Health Alliance, Harvard Medical School, Cambridge, MA, USA
J Am Acad Child Adolesc Psychiatry 46:979-88. 2007..We examined baseline demographic and clinical profiles of youths enrolled from 2001 to 2006 in the publicly funded multicenter, randomized controlled trial Treatment of Early-Onset Schizophrenia Spectrum Disorders... - 3-year follow-up of the NIMH MTA studyPeter S Jensen
Center for the Advancement of Children s Mental Health, Unit 78, Columbia University NYSPI, 1051 Riverside Drive, New York, NY 10027, USA
J Am Acad Child Adolesc Psychiatry 46:989-1002. 2007..This report examines 36-month outcomes, 2 years after treatment by the study ended... - Rationale, design, and methods of the Preschool ADHD Treatment Study (PATS)Scott Kollins
Department of Psychiatry, Duke University Medical Center, Durham, NC 27705, USA
J Am Acad Child Adolesc Psychiatry 45:1275-83. 2006..To describe the rationale and design of the Preschool ADHD Treatment Study (PATS)... - Parent versus teacher ratings of attention-deficit/hyperactivity disorder symptoms in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS)Desiree W Murray
Department of Psychiatry, Duke University Medical Center, Durham, NC 27710, USA
J Child Adolesc Psychopharmacol 17:605-20. 2007..To assess parent-teacher concordance on ratings of DSM-IV symptoms of attention-deficit/hyperactivity disorder (ADHD) in a sample of preschool children referred for an ADHD treatment study... - A prospective open trial of guanfacine in children with pervasive developmental disordersLawrence Scahill
Yale Child Study Center, P O Box 207900, New Haven, CT 06520, USA
J Child Adolesc Psychopharmacol 16:589-98. 2006..A common complaint for children with pervasive developmental disorder (PDD) is hyperactivity. The purpose of this pilot study was to gather preliminary information on the efficacy of guanfacine in children with PDD and hyperactivity... - Methylphenidate effects on functional outcomes in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS)Howard B Abikoff
New York University Child Study Center, 215 Lexington Avenue, New York, NY 10016, USA
J Child Adolesc Psychopharmacol 17:581-92. 2007.... - Comorbidity moderates response to methylphenidate in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS)Jaswinder K Ghuman
University of Arizona, 1501 N Campbell Avenue, Tucson, AZ 85724, USA
J Child Adolesc Psychopharmacol 17:563-80. 2007..The aim of this study was to examine whether demographic or pretreatment clinical and social characteristics influenced the response to methylphenidate (MPH) in the Preschoolers with ADHD Treatment Study (PATS)... - Clinical presentation of attention-deficit/hyperactivity disorder in preschool children: the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS)Kelly Posner
New York State Psychiatric Institute Columbia University, 1041 Riverside Drive, New York, NY 10032, USA
J Child Adolesc Psychopharmacol 17:547-62. 2007..The diagnosis and evaluation process will also be described... - The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomesJohn S March
Department of Psychiatry, Duke University Medical Center, Durham, NC 27710, USA
Arch Gen Psychiatry 64:1132-43. 2007..The Treatment for Adolescents With Depression Study evaluates the effectiveness of fluoxetine hydrochloride therapy, cognitive behavior therapy (CBT), and their combination in adolescents with major depressive disorder... - Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioningDenis G Sukhodolsky
The Child Study Center, Yale University, 230 South Frontage Road, New Haven, CT 06520, USA
J Abnorm Child Psychol 36:117-28. 2008..Limited data are available on the prevalence of anxiety in these children. We examined frequency and correlates of parent-rated anxiety symptoms in a large sample of children with PDD... - Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trialDavid Brent
University of Pittsburgh, Pittsburgh, Pennsylvania, USA
JAMA 299:901-13. 2008..There are no data to guide clinicians on subsequent treatment strategy...